Hepatitis C News and Research RSS Feed - Hepatitis C News and Research

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.

The hepatitis C virus is usually transmitted through contact with the blood of an infected individual and, most commonly, people catch it through sharing contaminated needles when injecting illegal drugs.

Hepatitis C infection is categorized into an acute and a chronic stage. The acute phase describes the first 6 months of infection when there are not necessarily any symptoms. Around one quarter of people manage to clear the infection during this stage before disease progresses to the chronic stage.

People who go on to develop chronic hepatitis C may develop jaundice which turns the skin and whites of the eyes yellow. This is caused by the build-up of a yellow-colored substance in the blood called bilirubin that would usually be broken down by the liver if it was healthy. Chronic infection may eventually cause fibrosis and scarring (cirrhosis) of the liver, liver cancer or end stage liver failure.

Hepatitis C can be treated with antiviral medications that that are designed to disrupt the multiplication of virus particles inside the body and prevent liver damage.
New analysis finds global improvements in life expectancy

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013). [More]
New study highlights importance of generating awareness about HCV testing, support and care

New study highlights importance of generating awareness about HCV testing, support and care

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care. [More]
New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

Advances in treatment for human immunodeficiency virus (HIV) have made it possible for people with HIV to survive much longer. As they age, however, many experience impaired thinking, memory loss, mood swings and other evidence of impaired mental function. [More]
New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

A new study from epidemiologists at Tufts University School of Medicine helps to identify communities with the greatest public health need in Massachusetts for resources relating to HIV/AIDS and hepatitis C. [More]
Potential new active substances for treating dengue virus

Potential new active substances for treating dengue virus

Researchers from Johannes Gutenberg University Mainz and the Julius Maximilian University of Würzburg are proposing potential new active substances for treating the dengue virus. Just like Ebola, dengue fever is also caused by a virus for which there is currently no cure and no vaccine and can be fatal. [More]
Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. [More]
Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
Joint therapy to counter HIV and HCV increases chance of success

Joint therapy to counter HIV and HCV increases chance of success

A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C. [More]
Leading medical experts across the UK call for radical scale up of liver disease treatment

Leading medical experts across the UK call for radical scale up of liver disease treatment

Leading medical experts today [Thursday 27 November] warn that rising numbers of deaths from liver disease - already the UK's third commonest cause of premature death - will be unavoidable without radical improvements in treatment and detection services, and tougher government policies to control the excessive alcohol use and obesity responsible for much of the national burden of liver disease. [More]
New cell therapy offers hope for patients with liver cirrhosis

New cell therapy offers hope for patients with liver cirrhosis

Liver disease patients could be helped by a new cell therapy to treat the condition. [More]
New study documents health dangers of male sex trade in Mexico City

New study documents health dangers of male sex trade in Mexico City

A new study documents the stark health dangers of the male sex trade in the streets, hotels, and discotheques of Mexico City. Lead author and health economist Omar Galárraga's point in making the grim assessment of the legal but perilous market is to find an incentive that might reduce the spread of HIV and other diseases in the nation's community of men who have sex with men. [More]
Bacterial protein flagellin can prevent and cure rotavirus infection

Bacterial protein flagellin can prevent and cure rotavirus infection

Activation of the innate immune system with the bacterial protein flagellin could prevent and cure rotavirus infection, which is among the most common causes of severe diarrhea, says a Georgia State University research team that described the method as a novel means to prevent and treat viral infection. [More]
Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center received a $3.5 million grant as part of the $10 million Health Care Innovation Award from the Center for Medicare & Medicaid Services to identify, diagnose and treat people with hepatitis C (HCV). [More]
New treatment regimen for hepatitis C in transplant patients produces promising results

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine. [More]
Study examines overall survival of patients with chronic HCV infection, cirrhosis

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA. [More]
Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection. [More]
Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014. [More]
Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash. [More]
Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”). [More]